Many tumor types, such as prostate cancer, have high expression or activity of several growth factor receptors, like the epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor, which perform their functions by activating Src (Blume-Jensen and Hunter, 2001; Pietras et al., 2003; Ferrara, 2004; Harari, 2004). This evidence concerns the gene SRC and neoplasm.